Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

43.35 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Jun 28, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 18,774
Open 43.35
Bid (Size) 43.45 (13)
Ask (Size) 43.47 (1)
Prev. Close 43.35
Today's Range 43.35 - 43.35
52wk Range 37.80 - 46.97
Shares Outstanding 5,385,189,617
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
GSK Selects Target the Future Grant Recipient in Innovation Challenge Supporting Multiple Myeloma Community
From GSK plc
Via Business Wire
Ideaya Nominates Potential First-In-Class Pol Theta Helicase Inhibitor In Collaboration With GSK
 
Via Benzinga

Performance

YTD
-0.73%
-0.73%
1 Month
-1.25%
-1.25%
3 Month
+0.14%
+0.14%
6 Month
-1.72%
-1.72%
1 Year
+8.70%
+8.70%

More News

Read More
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies
Via Benzinga
GSK Shares Encouraging Data From Chronic Hepatitis B Candidate
Via Benzinga
With Zero Revenue, Laekna Plays Chicken-And-Egg Game With Investors
Via Benzinga
Finally An Omicron-Blocking Shot? Sanofi, GSK Say Yes
Via Investor's Business Daily
Benzinga Before The Bell: Gun Safety Bill. Bill Gates's North Dakota Outrage, Sanofi-GSK's Covid-19 Vaccine's Omicron Efficacy And Other Top Financial Stories Friday, June 24
Via Benzinga
Sanofi-GSK's Beta-Containing COVID-19 Vaccine Shows Efficacy Against Omicron
Via Benzinga
Best Stocks For 2022 Recession
Via Talk Markets
Antibiotic Makers Adopt Their Own Environmental Safeguard Standards
Via Benzinga
GSK Shows Positive Pivotal Phase III Data For Its RSV Vaccine Candidate
Via Benzinga
This Pharmaceutical Company Is Moving Beyond CBD
Via Benzinga
Analyzing GSK's Short Interest
Via Benzinga
Morning Brief: Top Financial Stories Dominating on Monday, June 13
Via Benzinga
Sanofi-GSK's Next-Gen COVID-19 Booster Shows Potential Against Variants Of Concern
Via Benzinga
FDA Approves GSK's Measles Vaccine
Via Benzinga
Morning Brief: Top Financial Stories Dominating on Friday, June 10
Via Benzinga
Breakthroughs In Treating Killer Diseases Could Lengthen Life
Via FinancialNewsMedia
Topics Death
Exposures Death
GSK announces US FDA approval of PRIORIX for the prevention of measles, mumps and rubella in individuals 12 months of age and older
From GSK plc
Via Business Wire
Morning Brief: Top Financial Stories Dominating on Monday, June 6
Via Benzinga
The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More
Via Benzinga
Week In Review: Vivo Raises $600 Million In First Tranche Of China PE Fund
Via Talk Markets
6 Biotech Stocks to Buy Now Ahead of These June Catalysts
Via InvestorPlace
3 Undervalued Dividend Growth Stocks
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.